摘要
目的观察难治性哮喘采用氨溴索与孟鲁司特钠联合治疗的效果。方法选取96例难治性哮喘患者,按照随机抽签法分为对照组和观察组,每组48例,对照组给予氨溴索治疗,观察组给予氨溴索联合孟鲁司特钠治疗。比较两组临床症状缓解时间、发作次数、症状消失时间及治疗前后用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FVC占预计值百分比(FVC%)、FEV1占预计值百分比(FEV1%)。结果观察组症状缓解时间(2.03±0.47)d、症状消失时间(3.29±1.07)d均短于对照组的(3.59±0.83)、(7.53±2.43)d,发作次数(13.52±2.68)次少于对照组的(42.53±4.72)次,差异有统计学意义(P<0.05)。治疗后,观察组FVC、FEV1、FVC%及FEV1%水平分别为(4.03±0.67)L、(3.24±0.51)L、(85.36±9.88)%、(87.16±9.93)%,均高于对照组的(3.53±0.52)L、(2.79±0.42)L、(76.24±8.43)%、(79.23±9.04)%,差异有统计学意义(P<0.05)。结论临床采用氨溴索联合孟鲁司特钠治疗难治性哮喘疗效显著,可缓解患者临床症状,改善肺功能,有推广应用的价值。
Objective To observe the effect of ambroxol combined with montelukast sodium on clinical symptoms and lung function in patients with refractory asthma.Methods A total of 96 patients with refractory asthma were divided into a control group and an observation group according to the random lottery method,with 48 cases in each group.The control group was treated with ambroxol,and the observation group was treated with ambroxol and montelukast sodium.Both groups were compared in terms of remission time of clinical symptoms,attack frequency and symptom disappearance time,as well as the forced vital capacity(FVC),forced expiratory volume in one second(FEV1),percentage of FVC to the predicted value(FVC%)and percentage of FEV1 to the predicted value(FEV1%)before and after treatment.Results The remission time of clinical symptoms was(2.03±0.47)d and the symptom disappearance time was(3.29±1.07)d in the observation group,which were shorter than(3.59±0.83)and(7.53±2.43)d in the control group;the attack frequency(13.52±2.68)times in the observation group was less than(42.53±4.72)in the control group;the differences were statistically significant(P<0.05).After treatment,the levels of FVC,FEV1,FVC%and FEV1%in the observation group were(4.03±0.67)L,(3.24±0.51)L,(85.36±9.88)%,and(87.16±9.93)%,which were higher than(3.53±0.52)L,(2.79±0.42)L,(76.24±8.43)%,and(79.23±9.04)%in the control group,and the differences were statistically significant(P<0.05).Conclusion Ambroxol combined with montelukast sodium is effective in treating refractory asthma,which can relieve patients’clinical symptoms and improve the lung function of patients,and has the value of popularization and application.
作者
宫国旦
GONG Guo-dan(Zhuanghe Hospital of Traditional Chinese Medicine,Zhuanghe 116400,China)
出处
《中国现代药物应用》
2023年第4期122-124,共3页
Chinese Journal of Modern Drug Application
关键词
难治性哮喘
氨溴索
孟鲁司特钠
肺功能
Refractory asthma
Ambroxol
Montelukast sodium
Lung function
